Extracellular Matrix Alterations in Patients With Paroxysmal and Persistent Atrial Fibrillation
|
|
- Britney Atkins
- 6 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 52, No. 3, by the American College of Cardiology Foundation ISSN /08/$34.00 Published by Elsevier Inc. doi: /j.jacc Heart Rhythm Disorders Extracellular Matrix Alterations in Patients With Paroxysmal and Persistent Atrial Fibrillation Biochemical Assessment of Collagen Type-I Turnover Eleftherios M. Kallergis, MD,* Emmanuel G. Manios, MD,* Emmanuel M. Kanoupakis, MD,* Hercules E. Mavrakis, MD,* Dimitris A. Arfanakis, MD,* Niki E. Maliaraki, MD, Chrisovalantis E. Lathourakis, MD,* Gregory I. Chlouverakis, PHD,* Panos E. Vardas, MD, PHD, FESC, FACC* Crete, Greece Objectives Background Methods Results Conclusions We investigated whether the serum markers of collagen turnover differed in various forms of atrial fibrillation (AF) and in sinus rhythm (SR) in humans. Structural alterations and fibrosis have been implicated in the generation and perpetuation of AF. Serum C-terminal propeptide of collagen type-i (CICP), C-terminal telopeptide of collagen type-i (CITP), matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinases-1 were measured as markers of collagen synthesis and degradation in 70 patients with AF and 20 healthy control subjects in SR. C-terminal propeptide of collagen type-i and CITP were significantly higher in AF patients than in control subjects (91 27 ng/ml vs ng/ml, p and ng/ml vs ng/ml, p 0.001, respectively). Persistent AF patients had higher levels of CICP ( ng/ml vs ng/ml, p 0.001), but not CITP, compared with those with paroxysmal AF. Patients with persistent AF had lower levels of matrix metalloproteinase-1 but increased levels of tissue inhibitor of matrix metalloproteinases-1 compared with patients with paroxysmal AF ( ng/ml vs ng/ml, p 0.03 and ng/ml vs ng/ml, p 0.001, respectively). Tissue inhibitor of matrix metalloproteinases-1 levels were significantly lower in control subjects compared with those in both paroxysmal and persistent AF patients ( ng/ml vs ng/ml vs ng/ml, respectively, p 0.001). Serum markers of collagen type-i turnover differed significantly between patients with AF and SR. Furthermore, these markers also differed significantly between paroxysmal and persistent AF patients, suggesting that the intensity of the extracellular synthesis and degradation of collagen type-i may be related to the burden or type of AF. (J Am Coll Cardiol 2008;52:211 5) 2008 by the American College of Cardiology Foundation Recent data from cardiac biopsies of patients with atrial fibrillation (AF) have demonstrated a substantial increase in collagen deposition in the atria of humans with AF as opposed to those in sinus rhythm (SR) (1 3). Preliminary experimental and clinical data suggest that biochemical markers of collagen turnover correlate significantly with fibrosis in endomyocardial biopsies in hypertensive patients (4). However, although such markers have been shown to differ between hypertensive and normotensive individuals, studies of their association with hypertrophy or other echocardiographic parameters have produced inconsistent results (5,6). From the *Department of Cardiology and Laboratory of Biochemistry, University Hospital of Heraklion, Crete, Greece. Manuscript received October 29, 2007; revised manuscript received February 13, 2008, accepted March 18, Collagen type-i is the major collagenous product of cardiac fibroblasts (7). We assessed the amount of fibrosis in patients with paroxysmal or persistent lone AF using serum analysis of peptides derived from the tissue synthesis (Cterminal propeptide of collagen type-i [CICP]) and degradation (C-terminal telopeptide of collagen type-i [CITP]) of collagen type-i (4). Enzymes that control collagen type-i turnover, specifically matrix metalloproteinase (MMP)-1 and tissue inhibitor of matrix metalloproteinases (TIMP)-1, were also measured (8). Methods The ethics committee of our institution approved the study, which conformed to the principles outlined in the Declaration of Helsinki. Informed written consent was obtained from all subjects.
2 212 Kallergis et al. JACC Vol. 52, No. 3, 2008 Fibrosis and AF July 15, 2008:211 5 Abbreviations and Acronyms AF atrial fibrillation CICP C-terminal propeptide of collagen type-i CITP C-terminal telopeptide of collagen type-i LA left atrial LVEF left ventricular ejection fraction MMP matrix metalloproteinase SR sinus rhythm TIMP tissue inhibitor of matrix metalloproteinase The study population consisted of 70 ambulatory patients (age 24 to 78 years) who suffered from lone AF, defined as AF without clinical or echocardiographic evidence of cardiopulmonary disease, including hypertension. The arrhythmia was considered paroxysmal when it was self-terminating in 24 h and persistent when it was documented on sequential 12-lead electrocardiograms, without any intervening periods of SR, for at least 3 months preceding enrollment. Patients with persistent AF had been referred to our department for electrical cardioversion; none had undergone such a procedure before. No patient had permanent AF, defined as sustained arrhythmia despite cardioversion. Twenty healthy subjects in SR with no history of atrial arrhythmias served as a control group. Exclusion criteria were conditions associated with elevated serum concentrations of myocardial or tissue fibrosis markers, such as liver disease, renal impairment, pulmonary fibrosis, extensive wounds, metabolic bone disease, malignancy, connective tissue disorders, chronic inflammatory disease, and recent infection or surgery. Patients who were over 80 years old or had a pacemaker/implantable cardioverter-defibrillator were also excluded. Using a case-control study design, serological markers of collagen type-i turnover, echocardiographic maximal left atrial (LA) diameter, and left ventricular ejection fraction (LVEF) were compared in patients and control subjects. Diltiazem and beta-blockers were allowed for ventricular rate control, and all AF patients received the indicated antithrombotic treatment. All patients were in AF at the time of blood sampling. Blood samples were obtained at the time of the clinical studies and were immediately placed on ice and centrifuged within 1 h. Specimens were stored at 80 C until analysis. Serum TIMP-1 and MMP-1 levels were assayed by enzyme-linked immunoadsorbent assay with commercially available kits (Human Biotrack enzyme-linked immunoadsorbent assay system, Amersham Biosciences, Piscataway, New Jersey). C-terminal propeptide of collagen type-i levels were determined by a sandwich enzyme immunoassay with a commercially available kit (enzyme immunoassay, Metra CICP, Quidel, San Diego, California), while CITP was measured using the Elecsys -CrossLaps/serum assay (Roche Diagnostics, Mannheim, Germany). Measurements were performed by personnel blinded to the patients clinical details. The intra- and interassay coefficients of variation of all assays were 8% and 10%, respectively, in our laboratory. Statistical analysis. Summary descriptive statistics for continuous parameters are presented as mean SD. Categorical variables were compared among the persistent, paroxysmal AF, and control groups using the chi-square test. One-way analysis of variance was used to test whether these 3 groups differed with respect to various continuous parameters of interest. Where findings were significant, post-hoc Tukey tests were performed to pinpoint differences. If the homogeneity of variance assumption was violated, the nonparametric Kruskal-Wallis test was used instead. Stepwise logistic regression analysis was used to assess whether age, gender, LA, and fibrosis markers were independently associated with AF. Age, LA, and fibrosis markers were treated as continuous variables in the model. The thresholds for entry into and removal from the model were 5% and 10%, respectively. Associations between continuous variables of interest were assessed with correlation and linear regression techniques. Values of p 0.05 were considered statistically significant. Results Patients. The baseline clinical and demographic features of the study population are shown in Table 1. Thirty-two patients had persistent and 38 paroxysmal AF. There were no significant differences in gender (p 0.40) or age (p 0.058) between the AF groups. Control subjects were younger than AF patients (p 0.001), but were comparable in terms of gender distribution. Patients with persistent AF had lower LVEF (p 0.038) and a larger LA (p 0.001) compared with paroxysmal AF patients. Serum markers of collagen turnover. The findings are summarized in Table 1. Both CICP and CITP levels were significantly higher in persistent AF patients than in control subjects (p 0.016). Persistent AF patients also had higher CICP levels compared with those with paroxysmal AF (p 0.001), whereas there was no significant difference in CITP levels (p 0.57) (Table 1, Figs. 1 and 2). Patients with persistent AF had lower levels of MMP-1 (p 0.026) but higher levels of TIMP-1 (p 0.013) compared with patients with paroxysmal AF (Table 1, Figs. 3 and 4). Tissue inhibitor of matrix metalloproteinases-1 levels were significantly lower (p 0.001) in control subjects compared with both paroxysmal and persistent AF patients (Fig. 4). Plasma MMP-1 levels did not differ significantly (p 0.20) between persistent AF patients and control subjects (Fig. 3). Finally, in all AF patients taken together, there was a positive correlation between both CICP and TIMP levels and LA dimension (r 0.635, p and r 0.563, p 0.001, respectively) (Fig. 5), while there was a weak, inverse relation between CICP and TIMP levels and LVEF (r 0.234, p 0.05 and r 0.278, p 0.020, respectively). A positive correlation was also observed between MMP-1 levels and LVEF (r 0., p 0.012) while there was an inverse relation between MMP-1 levels
3 JACC Vol. 52, No. 3, 2008 July 15, 2008:211 5 Baseline Patients Characteristics With Persistent andorserum Paroxysmal Markers AFof and Collagen HealthyType-I Control Turnover Subjects in SR Table 1 Baseline Characteristics and Serum Markers of Collagen Type-I Turnover in Patients With Persistent or Paroxysmal AF and Healthy Control Subjects in SR Kallergis et al. Fibrosis and AF 213 Persistent AF (n 32) Paroxysmal AF (n 38) Control Subjects (n 20) p Value Age (yrs) Gender (M/F) 23/9 27/11 12/ LVEF (%) LA (mm) BMI (kg/m 2 ) SBP (mm Hg) DBP (mm Hg) CICP CITP MMP TIMP Values are expressed as mean SD. Post-hoc analysis showed that: 1) age and left atrial diameter (LA) differed significantly between control subjects and persistent atrial fibrillation (AF) patients; 2) C-terminal propeptide of collagen type-i (CICP) levels in persistent AF patients differed significantly compared with both paroxysmal and control subjects; 3) C-terminal telopeptide of collagen type-i (CITP) levels in control subjects differed significantly compared with both paroxysmal and persistent AF patients; 4) matrix metalloproteinase (MMP)-1 levels differed significantly between persistent and paroxysmal AF patients; and 5) tissue inhibitor of matrix metalloproteinase (TIMP)-1 levels differed significantly in all intergroup comparisons. BMI body mass index; DBP diastolic blood pressure; LVEF left ventricular ejection fraction; SBP systolic blood pressure; SR sinus rhythm. and LA dimension (r 0.615, p 0.001). Logistic regression analysis showed that, among age, gender, LA and collagen markers, TIMP-1, MMP-1, age, and CICP were independently associated with AF (Table 2). Discussion Patients initially presenting with paroxysmal AF often progress to persistent and eventually develop permanent AF. Although the exact pathophysiological mechanisms are poorly understood, persistence of AF is thought to result from atrial remodeling (9,10). However, pure electrical remodeling cannot explain the development of sustained AF (10,11). Atrial fibrosis, a factor with a slower time course, could be involved (3,12,13). In this study we demonstrated an elevation in CICP and CITP in the AF cohort taken as a whole compared with those in SR. Interestingly, persistent AF patients had the highest serum concentrations of CICP, whereas there was no difference in CITP levels between patients with persistent and paroxysmal AF. Thus, CICP demonstrated a gradual increase from control subjects to paroxysmal and then to persistent AF, but CITP did not, suggesting that the intensity of the extracellular degradation of collagen type-i was insufficient to compensate for its increased synthesis, resulting in augmented fibrosis in patients with persistent AF. Furthermore, in patients with persistent AF, MMP-1 levels were decreased, whereas TIMP-1 levels were increased compared with paroxysmal AF patients. Levels of TIMP-1 were also higher in paroxysmal AF patients than in control subjects. In addition, control subjects had lower levels of MMP-1 than paroxysmal AF patients but higher CICP CITP Figure 1 Comparative Levels of Serum Concentration of CICP Figure 2 Box Plot of Serum Concentrations of CITP C-terminal propeptide of collagen type-i (CICP) showed a gradual increase from control subjects to paroxysmal and then to persistent atrial fibrillation (AF) patients as shown in this box plot. C-terminal telopeptide of collagen type-i (CITP) in control subjects differed significantly compared with that in both paroxysmal and persistent atrial fibrillation (AF) patients.
4 214 Kallergis et al. JACC Vol. 52, No. 3, 2008 Fibrosis and AF July 15, 2008:211 5 MMP CICP Persistent AF Paroxysmal AF 5 0 Controls Persistent AF Paroxysmal AF LA (mm) Figure 3 Intergroup Serum Concentrations of MMP-1 This box plot depicts matrix metalloproteinase (MMP)-1 levels that differed significantly between persistent and paroxysmal atrial fibrillation (AF) patients. levels than persistent AF patients (although the differences did not reach statistical significance). That seems paradoxical, but it could be the result of the activation manner of MMP-1, which depends on the nature of the stimulus and differs in the setting of acute or chronic stimulation (14). Thus, short-lasting paroxysmal AF could result acutely in pressure or volume overload, activating the MMP-1 system, which then becomes compromised with the prolongation and stabilization of the stimulus. Another interesting finding was that both CICP and TIMP levels positively correlated with LA diameter and inversely related to LVEF, whereas AF patients with a larger LA and a smaller LVEF, probably as a result of a longer arrhythmia duration, had lower MMP-1 levels. Since our study included patients with lone AF only, we can speculate that the aforementioned alterations were TIMP1 Figure Box Plot Depiction of the Differences in Levels of Serum TIMP-1 Tissue inhibitor of matrix metalloproteinase (TIMP)-1 levels differed significantly in all intergroup comparisons. AF atrial fibrillation. Figure 5 Direct Correlation Between Serum Concentrations of CICP and LA Diameter Dimensions In all AF patients taken together, there was a positive correlation between CICP and left atrial diameter (LA) dimension (r 0.635, p 0.001). Abbreviations as in Figure 1. attributable to the arrhythmia itself, and not to the presence or absence of any confounding factor, with a progressive increase in fibrosis from paroxysmal to persistent AF. In addition, the augmented fibrosis, especially in patients with the persistent form of AF, could further suggest that if collagen modification plays a causal role, this relates to both the initiation and the maintenance of AF. Study limitations and clinical implications. Serum markers of collagen turnover are not heart specific. In addition, we did not support our findings with atrial tissue biopsy data or coronary sinus sampling. However, we made strenuous efforts to exclude subjects with conditions associated with fibrosis. Despite our efforts to match control subjects with AF patients, the latter were older. However, collagen markers differed significantly between patients with persistent and paroxysmal AF, despite the lack of any significant difference in age, suggesting that age differences did not influence the interpretation of our results. Serial measurements of collagen indexes after SR restoration to evaluate the potential temporal alterations of collagen turnover are not available, although these data would undoubtedly have been a valuable addition to our study and could have reinforced our findings. Independent to Stepwise Logistic Predictors Regression of AF According Analysis Table 2 Independent Predictors of AF According to Stepwise Logistic Regression Analysis Variable Odds Ratio 95% CI p Value TIMP MMP Age CICP CI confidence interval; other abbreviations as in Table 1.
5 JACC Vol. 52, No. 3, 2008 July 15, 2008:211 5 Kallergis et al. Fibrosis and AF 215 Finally, the small patient sample size does not allow major conclusions regarding the relationship between systemic fibrosis and AF. Given these limitations, this is the first study to estimate the relationship between AF burden and serum markers of collagen type-i synthesis and degradation, demonstrating a potential role for these markers in AF evaluation. Conclusions Serum markers of collagen type-i turnover may provide a noninvasive method of documenting and monitoring both the extent and the mechanisms of myocardial fibrosis in AF patients and of evaluating pharmacological measures designed to treat this arrhythmia. However, further investigation and randomized trials are needed to elucidate the exact role of fibrosis in AF and to evaluate the clinical importance and value of biochemical monitoring of collagen turnover in this clinical setting. Although cardiac biopsy is the gold standard for documenting and monitoring myocardial fibrosis, noninvasive methods offer a particularly attractive alternative that could have a broader application. Reprint requests and correspondence: Dr. Panos E. Vardas, Department of Cardiology, Heraklion University Hospital, 71100, Heraklion, Crete, Greece. cardio@med.uoc.gr. REFERENCES 1. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96: Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004;90: Bishop JE. Regulation of cardiovascular collagen deposition by mechanical forces. Mol Med Today 1998;4: López B, González A, Varo N, Laviades C, Querejeta R, Díez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38: Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type-i in essential hypertension. Circulation 1998;8: Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40: Lijnen P, Petrov V, Fagard R. Induction of cardiac fibrosis by transforming growth factor-b1. Mol Genet Metab 2000;71: Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;46: Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92: Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54: Yu WC, Lee SH, Tai CT, et al. Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man. Cardiovasc Res 1999;42: Kostin S, Klein G, Szalay Z, Hein S, Bauer E, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002;54: Janse MJ. Why does atrial fibrillation occur? Eur Heart J 1997; 18: Nagatomo Y, Carabello BA, Coker ML, et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol 2000;278:H Key Words: atrial fibrillation y collagen y fibrosis.
Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro
Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Jerónimo Farré MD, Madrid, ES AF: the kingdom of wishful thinking In AF we
More informationThe role of spironolactone in the metabolism of serum type I collagen in elderly patients with atrial fibrillation
European Review for Medical and Pharmacological Sciences The role of spironolactone in the metabolism of serum type I collagen in elderly patients with atrial fibrillation S.-H. ZHANG, J. WANG, T.-R. JIN,
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationCatheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD
Catheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD Taipei Veterans General Hospital, Taiwan Outline of AF Ablation 1. Strategy for Catheter Ablation of AF 2. Substrate
More informationProgression From Paroxysmal to Persistent Atrial Fibrillation
Journal of the American College of Cardiology Vol. 55, No. 8, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.11.040
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationAdvanced imaging of the left atrium - strain, CT, 3D, MRI -
Advanced imaging of the left atrium - strain, CT, 3D, MRI - Monica Rosca, MD Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Declaration of interest: I have nothing to declare Case
More informationNew Parameter to Predict Recurrence of Paroxysmal Atrial Fibrillation after Pulmonary Vein Isolation by the P-Wave Signal-Averaged Electrocardiogram
Showa Univ J Med Sci 29 2, 141 150, June 2017 Original New Parameter to Predict Recurrence of Paroxysmal Atrial Fibrillation after Pulmonary Vein Isolation by the P-Wave Signal-Averaged Electrocardiogram
More informationTitle: Left atrium size in former elite athletes
Title: Left atrium size in former elite athletes Short title: exercise and left atrium Authors: Fabian Sanchis-Gomar, MD, PhD, a Nuria Garatachea, PhD, a,b Pilar Catalán, MD, c Marta López, MD, d Alejandro
More informationPrognostic Value of Cardiopulmonary Exercise Testing in Patients with Atrial Fibrillation
Prognostic Value of Cardiopulmonary Exercise Testing in Patients with Atrial Fibrillation Hidekazu Tsuneoka 1)2), Akira Koike 2), Osamu Nagayama 2), Koji Sakurada 2), Hitoshi Sawada 2), Kazutaka Aonuma
More informationA bout 1% of the population suffers from atrial fibrillation
400 CARDIOVASCULAR MEDICINE Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease A Boldt, U Wetzel, J Lauschke, J Weigl, J Gummert, G Hindricks,
More informationDegenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention
Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention John N. Hamaty D.O. FACC, FACOI November 17 th 2017 I have no financial disclosures Primary Mitral
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationPathophysiology of heart failure with preserved ejection fraction. Extracellular matrix
Pathophysiology of heart failure with preserved ejection fraction Extracellular matrix Javier Díez, MD, PhD. Full Professor of Cardiovascular Medicine and Director Division of Cardiovascular Sciences Centre
More informationPericardial Fat Is Independently Associated With Human Atrial Fibrillation
Journal of the American College of Cardiology Vol. 56, No. 10, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.03.071
More informationAF ABLATION Concepts and Techniques
AF ABLATION Concepts and Techniques Antony F Chu, M.D. Director of Complex Ablation Arrhythmia Services Section Division of Cardiology at the Rhode Island and Miriam Hospital HIGHLIGHTS The main indications
More informationAtrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA
Atrial fibrillation: a key determinant in the cardiovascular risk continuum u Prof. Joseph S. Alpert u Arizona, USA Disclosures u No major conflicts of interest: all honoraria
More informationLong-Term Atrial Fibrillation Progression: What We Know in 2014
Long-Term Atrial Fibrillation Progression: What We Know in 2014 Advances in Cardiac Arrhythmias and Great Innovations in Cardiology XXVI Giornate Cardiologiche Torinesi Turin, 23-25 October 2014 Davide
More informationΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C
ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C Definitions of AF: A Simplified Scheme Term Definition Paroxysmal AF AF that terminates
More informationDeposited on: 29 October 2009
Workman, A.J. (2009) Mechanisms of postcardiac surgery atrial fibrillation: more pieces in a difficult puzzle. Heart Rhythm, 6 (10). pp. 1423-1424. ISSN 1547-5271 http://eprints.gla.ac.uk/7847/ Deposited
More informationJournal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, 9, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.04.062 Relation
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationSupplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
More informationWho Gets Atrial Fibrilla9on..?
Birmingham October 20 th 2013 AFA Pa9ents Day Symptoma9c Atrial Fibrilla9on What therapies are available? GENERAL BACKGROUND Andrew Grace Papworth Hospital and University of Cambridge Consultant: Medtronic
More informationProf. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.
Obesity as a risk factor for Atrial Fibrillation Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept. CardioAlex 2010 smrafla@hotmail.com 1 Obesity has reached epidemic proportions in the United
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationEHRA/EUROPACE 2011 Madrid, Spain June
EHRA/EUROPACE 2011 Madrid, Spain June 26.-29.2011 Implementing modern management in atrial fibrillation patients Proceedings from the 3rd AFNet/EHRA consensus conference EHRA Special Session Different
More informationDeclaration of conflict of interest. None to declare
Declaration of conflict of interest None to declare Risk management of coronary artery disease Arrhythmias and diabetes Hercules Mavrakis Cardiology Department Heraklion University Hospital Crete, Greece
More informationThe extracellular matrix is a dynamic structure, with
Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1? Francisco Marín, MD; Vanessa Roldán, MD; Vicente Climent, MD; Amaya García, MD; Pascual Marco,
More informationEchocardiographic Correlates of Pulmonary Artery Systolic Pressure
Echocardiographic Correlates of Pulmonary Artery Systolic Pressure The Role of Left Ventricular Diastolic Function Yoram Agmon MD, Shemy Carasso MD, Diab Mutlak MD, Jonathan Lessick MD Dsc, Izhak Kehat
More informationBiphasic Clinical Summaries
Biphasic Clinical Summaries Defibrillation of Ventricular Fibrillation and Ventricular Tachycardia Background Physio-Control conducted a multi-centered, prospective, randomized and blinded clinical trial
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationInterventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
More informationATRIAL FIBRILLATION AND LEFT ATRIUM: STRUCTURAL REMODELING AND EVOLUTION OF ARRHYTHMIA PATTERN
Atrial Fibrillation and Heart Failure: the ugly and the nasty 13 International Meeting February 14-15 th 2019, Bologna ATRIAL FIBRILLATION AND LEFT ATRIUM: STRUCTURAL REMODELING AND EVOLUTION OF ARRHYTHMIA
More informationTime to Cardioversion of Recurrent Atrial Arrhythmias After Catheter Ablation of Atrial Fibrillation and Long-Term Clinical Outcome
Time to Cardioversion of Recurrent Atrial Arrhythmias After Catheter Ablation of Atrial Fibrillation and Long-Term Clinical Outcome TIMIR S. BAMAN, M.D., SANJAYA K. GUPTA, M.D., SREEDHAR R. BILLAKANTY,
More informationImprovement in collagen metabolism after 12 weeks cardiac resynchronization therapy in patients with ischaemic cardiomyopathy
Research Report Improvement in collagen metabolism after 12 weeks cardiac resynchronization therapy in patients with ischaemic cardiomyopathy Journal of International Medical Research 41(1) 200 207! The
More informationTHE ISSUE OF RESTITUTION AND MAINTENANCE OF SINUS RHYTHM IN ATRIAL FIBRILLATION
UNIVERSITY LUCIAN BLAGA SIBIU UNIVERSITY OF MEDICINE VICTOR PAPILIAN SIBIU DOCTORAL THESIS THE ISSUE OF RESTITUTION AND MAINTENANCE OF SINUS RHYTHM IN ATRIAL FIBRILLATION - ABSTRACT - PhD student Mentor
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationAtrial fibrillation: the remodelling phenomenon
European Heart Journal Supplements (2003) 5 (Supplement H), H1 H7 Atrial fibrillation: the phenomenon G.L. Botto, M. Luzi and A. Sagone Department of Cardiology, St Anna Hospital, Como, Italy KEYWORDS
More informationAtrial fibrillation: the remodelling phenomenon
European Heart Journal Supplements (2003) 5 (Supplement H), H1 H7 Atrial fibrillation: the phenomenon G.L. Botto, M. Luzi and A. Sagone Department of Cardiology, St Anna Hospital, Como, Italy KEYWORDS
More informationEarly Recurrence of Atrial Fibrillation After Ambulatory Shock Conversion
Journal of the American College of Cardiology Vol. 40, No. 1, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01912-5
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationHigh Risk OSA n = 5,359
Table S1 Prevalence of atrial fibrillation (AF) identified using different methods in participants with high and low risk obstructive sleep apnea (). High Risk n = 5,359 Low Risk n = 14,992 SR-AF (%) 467
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationIs cardioversion old hat? What is new in interventional treatment of AF symptoms?
Is cardioversion old hat? What is new in interventional treatment of AF symptoms? Joseph de Bono Consultant Electrophysiologist University Hospitals Birmingham Atrial Fibrillation (AF) Affects 2% of the
More informationControversies with regard to 'upstream therapy of atrial fibrillation
Controversies with regard to 'upstream therapy of atrial fibrillation Barbara Casadei Department of Cardiovascular Medicine John Radcliffe Hospital University of Oxford No conflict of interest to declare
More informationConcomitant Recovery of Atrial Mechanical and Endocrine Function After Cardioversion in Patients With Persistent Atrial Fibrillation
Journal of the American College of Cardiology Vol. 41, No. 10, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00306-1
More informationCongestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationJournal of the American College of Cardiology Vol. 43, No. 2, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 43, No. 2, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.08.037
More informationExpression of Angiotensin II Receptors in Human Left and Right Atrial Tissue in Atrial Fibrillation With and Without Underlying Mitral Valve Disease
Journal of the American College of Cardiology Vol. 42, No. 10, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.07.014
More informationThe RealiseAF registry:
The RealiseAF registry: An International, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of AF patients initial results PG.Steg on behalf
More informationDigoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD, PhD, FACC on behalf of the ARISTOTLE Investigators
More informationPrediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring
Prediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring Yu-Zhen ZHANG, M.D.,* Shi-Wen WANG, M.D.,* Da-Yi Hu, M.D.,**
More informationLinköping University Post Print. Atrial fibrillation and platelet reactivity
Linköping University Post Print Atrial fibrillation and platelet reactivity Micha Milovanovic, Elisabeth Fransson, Claes Hallert and Petter Järemo N.B.: When citing this work, cite the original article.
More informationHeart Failure Challenges and Unmet needs
Heart Failure Challenges and Unmet needs. Angelo Auricchio, MD FESC Director, Cardiac Electrophysiology Programme, Fondazione Cardiocentro Ticino, Lugano, Switzerland Professor of Cardiology, University
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationRestrictive Cardiomyopathy
ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures
More informationInflammation in heart failure: biomarker, bystander or mediator
Inflammation in heart failure: biomarker, bystander or mediator Novel matricellular proteins to target Javier Díez, MD, PhD. Centre of Applied Medical Research and University Clinic School of Medicine,
More informationAbstract nr. 1 Abstract code Hybrid Versus Catheter Ablation for Atrial Fibrillation: the HARTCAP-AF Trial
Abstract nr. 1 Hybrid Versus Catheter Ablation for Atrial Fibrillation: the HARTCAP-AF Trial Auteur Vroomen, M., Maastricht University Medical Center, Maastricht, Nederland Co-auteur(s) - La Meir, M. Co-auteur(s)
More informationAntifibrotic Therapy Delays Progression from Paroxysmal to Persistent Atrial Fibrillation
Antifibrotic Therapy Delays Progression from Paroxysmal to Persistent Atrial Fibrillation José Jalife, M.D. Center for Arrhythmia Research University of Michigan No Disclosures The mechanisms that maintain
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationCatheter Ablation: Atrial fibrillation (AF) is the most common. Another Option for AF FAQ. Who performs ablation for treatment of AF?
: Another Option for AF Atrial fibrillation (AF) is a highly common cardiac arrhythmia and a major risk factor for stroke. In this article, Dr. Khan and Dr. Skanes detail how catheter ablation significantly
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationUniversity of Groningen. Atrial remodeling due to atrial tachycardia and heart failure Schoonderwoerd, Bas Arjan
University of Groningen Atrial remodeling due to atrial tachycardia and heart failure Schoonderwoerd, Bas Arjan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationConflict of interest: none declared
The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracycline-mediated cardiotoxicity C. Mornoş, A. Ionac, D. Cozma, S. Pescariu,
More informationE LeAP STUDY ECHOCARDIOGRAPHIC LEFT ATRIAL PRESSURE: COMPARATIVE REVIEW IN PATIENTS WITH SINUS RHYTHM AND ATRIAL FIBRILLATION
E LeAP STUDY ECHOCARDIOGRAPHIC LEFT ATRIAL PRESSURE: COMPARATIVE REVIEW IN PATIENTS WITH SINUS RHYTHM AND ATRIAL FIBRILLATION Moghniuddin Mohammed, M.B.B.S. Mentor: Dr. Harry McCrea, M.D. Dr. Yuji Saito,
More informationDIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI.
DIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI. Franco Cipollini, Carlo Porta, Enrica Arcangeli, Carla Breschi, & Giuseppe Seghieri Azienda USL 3, Ambulatorio
More informationAtrial fibrillation in the ICU
Atrial fibrillation in the ICU Atrial fibrillation Preexisting or incident (new onset) among nearly one in three critically ill patients Formation of arrhythogenic substrate usually fibrosis (CHF, hypertension,
More informationThe Incidence and Predictors of Postoperative Atrial Fibrillation After Noncardiothoracic Surgery
ORIGINAL ARTICLE DOI 10.4070 / kcj.2009.39.3.100 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology The Incidence and Predictors of Postoperative Atrial Fibrillation
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationRelationship Between Serum Biochemical Markers of Myocardial Fibrosis and Diastolic Function at Rest and With Exercise in Hypertrophic Cardiomyopathy
ORIGINAL ARTICLE DOI 10.4070 / kcj.2009.39.12.519 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology Open Access Relationship Between Serum Biochemical Markers
More informationHypertrophic cardiomyopathy (HCM) is characterized by
Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy Raffaella Lombardi, MD; Sandro Betocchi, MD; Maria Angela Losi, MD; Carlo Gabriele Tocchetti, MD; Mariano Aversa, MD; Marianna Miranda, MD; Gianluigi
More informationHFPEF Echo with Strain vs. MRI T1 Mapping
HFPEF Echo with Strain vs. MRI T1 Mapping Erik Schelbert, MD MS Director, Cardiovascular Magnetic Resonance Assistant Professor of Medicine Heart & Vascular Institute University of Pittsburgh Disclosures
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationAtrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction
Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction JC Eicher, G Laurent, O Barthez, A Mathé, G Bertaux, JE Wolf Heart Failure Treatment Unit, Rhythmology and
More informationTime Course for Resolution of Left Atrial Appendage Stunning After Catheter Ablation of Chronic Atrial Flutter
Journal of the American College of Cardiology Vol. 41, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00496-0
More informationTachycardia-induced heart failure - Does it exist?
Tachycardia-induced heart failure - Does it exist? PD Dr Etienne Delacrétaz Clinique Cecil et Hôpital de Fribourg SSC Cardiology meeting 2015 Zürich Rapid atrial fibrillation is a common cause of heart
More informationAblation of persistent AF Is it different than paroxysmal?
Ablation of persistent AF Is it different than paroxysmal? Steven J. Kalbfleisch, MD Medical Director Electrophysiology Laboratory Ohio State University Wexner Medical Center Ross Heart Hospital Columbus,
More informationDr. Dermot Phelan MB BCh BAO PhD European Society of Cardiology 2012
Relative Apical Sparing of Longitudinal Strain Using 2- Dimensional Speckle-Tracking Echocardiography is Both Sensitive and Specific for the Diagnosis of Cardiac Amyloidosis. Dr. Dermot Phelan MB BCh BAO
More informationPossible clinical and hemodynamic predictors of atrial fibrillation recurrence after catheter ablation
Samara Regional Center of Cardiosurgery Possible clinical and hemodynamic predictors of atrial fibrillation recurrence after catheter ablation S. Dolginina, S. Garkina, S. Khokhlunov, D. Duplyakov Russia
More informationAtrial fibrillation (AF), one of the most common arrhythmias
Atrial Extracellular Matrix Remodeling and the Maintenance of Atrial Fibrillation Jun Xu, MD, PhD; Guanggen Cui, MD; Fardad Esmailian, MD; Mark Plunkett, MD; Daniel Marelli, MD; Abbas Ardehali, MD; Jonah
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationAtrial Cardiomyopathy is it relevant?
Atrial Cardiomyopathy is it relevant? Dr Carl Shakespeare MD FRCP FACC FESC Consultant Cardiologist Relevance Progressive nature of AF Implications for RF Targeting Risk Factors CHADS vasc scoring? Could
More informationDiscordant Atrial Natriuretic Peptide and Brain Natriuretic Peptide Levels in Lone Atrial Fibrillation
Journal of the American College of Cardiology Vol. 45, No. 1, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.09.045
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationTiming of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism
7 Frederikus A. Klok Noortje van der Bijl Inge C.M. Mos Albert de Roos Lucia J. M. Kroft Menno V. Huisman Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism Letter
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationChronic Primary Mitral Regurgitation
Chronic Primary Mitral Regurgitation The Case For Early Surgical Intervention William K. Freeman, MD, FACC, FASE DISCLOSURES Relevant Financial Relationship(s) None Off Label Usage None Watchful Waiting......
More informationROLE OF IMAGING IN ARRHYTHMIA/DEVICES I ATRIAL FΙBRILLATION: CLINICAL TYPES AND OUTCOME (PROGNOSIS)
ROLE OF IMAGING IN ARRHYTHMIA/DEVICES I ATRIAL FΙBRILLATION: CLINICAL TYPES AND OUTCOME (PROGNOSIS) Κώστας Παπαδόπουλος, Επιμ. Α Καρδιολογίας, Νοσοκομείο Ερυθρός Σταυρός ATRIAL FIBRILATION - EPIDEMIOLOGY
More informationLeft Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient
Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient Dr. Peersab.M. Pinjar 1, Dr Praveenkumar Devarbahvi 1 and Dr Vasudeva Murthy.C.R 2, Dr.S.S.Bhat 1, Dr.Jayaraj S G 1
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More information